GlaxoSmithKline Pharmaceuticals Limited Share Price and Company Fundamentals
Last traded: Last Friday at 9:59 AM
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and Trelegy Ellipta for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, an oral antibiotic to treat bacterial infections; CobadexCZS to treat mineral and vitamins deficiency states in adult patients; Flutivate, a skin cream for adults, children and infants; Tenovate to treat inflammatory and pruritic manifestations of steroid responsive dermatosis; CALPOL to treat mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment of specific bacterial skin infections; BETNOVATE for skin conditions; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin associated with redness and itch. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited operates as a subsidiary of GSK plc.
Key Metrics
PE ratio
40.00
PB ratio
23.96
Dividend yield
1.73%
Beta
-0.03
Market cap
₹409.12B
Enterprise value
₹390.45B
Company profile
| Industry / Sector | Drug Manufacturers - General / Healthcare |
|---|---|
| Full time employees | 3113 |
| Website | https://india-pharma.gsk.com |
| Mailing address | GSK House Dr. Annie Besant Road Worli Mumbai 400030 India |
| Phone / Fax | 91 22 2495 9595 / 91 22 2495 9494 |
Dividends
Dividend yield
1.73%
Dividend amount
₹42.00
Payout ratio
69.69%
5Y Avg. yield
-%
GlaxoSmithKline Pharmaceuticals Limited paid ₹42.00 dividend and the ex-dividend date was 30 May 2025.The dividend payout ratio is 69.69%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.GLAXO dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Mar 2026, following are the company executives and directors listed on GlaxoSmithKline Pharmaceuticals Limited.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Mr. Bhushan Akshikar | MD & Executive Director | ||
| Ms. Aparajita Rajput | Vice President of Technology | ||
| Mr. Ajay Avinash Nadkarni | VP of Administration & Real Estate and Company Secretary | ||
| Mr. Amit G. Pandey | Executive Vice President of Legal | ||
| Dr. Simrat Sohal | Vice President of Ethics & Compliance | ||
| Mr. Carson Dalton | Executive Vice President of Communications & Government Affairs | ||
| Mr. Harsh V. Trehan | Executive Vice President of Human Resources | ||
| Ms. Sukanya Choudhary | Executive Vice President of Regulatory Affairs | ||
| Dr. Shalini Menon | Executive Vice President of Medical Affairs | ||
| Mr. Rishikesh S. Jaiwant | Executive Vice President of Supply Chain Operations |
Profitability and management effectiveness
Profit margin
26.86%
Operating margin
33.71%
Return on assets
-
Return on equity
-
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of GlaxoSmithKline Pharmaceuticals Limited is 409.12B and its enterprise value is 390.45B. The enterprise value to revenue ratio of GLAXO is 10.27. The enterprise value to EBITDA ratio of GLAXO is 30.91.
GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Frequently Asked Questions
1. What is GlaxoSmithKline Pharmaceuticals Limited's Stock Symbol?
GlaxoSmithKline Pharmaceuticals Limited trades on NSE under the ticker symbol "GLAXO".
2. What is GlaxoSmithKline Pharmaceuticals Limited's stock price today?
One share of GLAXO stock can currently be purchased for approximately ₹2415.
3. How can I contact GlaxoSmithKline Pharmaceuticals Limited?
GlaxoSmithKline Pharmaceuticals Limited's mailing address is GSK House Dr. Annie Besant Road Worli Mumbai 400030 India. The company can be reached via phone at 91 22 2495 9595.
4. What is GlaxoSmithKline Pharmaceuticals Limited's official website?
The official website of GlaxoSmithKline Pharmaceuticals Limited is https://india-pharma.gsk.com.